| Rachel Lynn Siffring, DNP, FNP-BC | |
|
553 Clinton Ave, Albany, NY 12206-2738 | |
| (518) 689-0282 | |
| Not Available |
| Full Name | Rachel Lynn Siffring |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 6 Years |
| Location | 553 Clinton Ave, Albany, New York |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1912550658 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | APN0000025599 (Tennessee) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Koinonia Primary Care Inc | 6901041425 | 4 |
News Archive
Recently, a group of researchers analyzed 122 pregnant women and their neonates at the time of birth. All the women studied received 1 or both doses of a messenger RNA (mRNA)-based vaccine for COVID-19. Of the 122 women part of the study, 55 had received only the first dose of the vaccine while 67 women had received both doses of the mRNA vaccine by the time they gave birth; 85 women had received the Pfizer-BioNTech vaccine, and 37 women received the Moderna vaccine. The study is published on the preprint server, bioRxiv.
Approximately one-quarter of inter-birth intervals in low- and middle-income countries are less than 24 months in length, exposing infants to risks of prematurity, low birthweight, and death. Increased evidence of these health risks has emerged in the past few decades and, after a period of neglect, interest in postpartum family planning has followed, supported by organizations like WHO and USAID.
Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that the first patient was dosed in a Phase 1 pharmacokinetic clinical trial using Enhanze™ Technology (rHuPH20, recombinant human hyaluronidase) in a subcutaneous formulation of a Roche biologic.
Hotspur Technologies, announced today that Dr. Greg Sampognaro, Interventional Cardiologist at P & S Surgical Hospital in Monroe, Louisiana, successfully completed the first use of the GPSCath Balloon Dilatation Catheter in an intervention to treat a blocked peripheral artery.
PharmAthene, Inc. announced today that it has achieved significant progress in the development of its second generation anthrax vaccine, SparVax.
› Verified 4 days ago
| Entity Name | Koinonia Primary Care Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023389533 PECOS PAC ID: 6901041425 Enrollment ID: O20130403000334 |
News Archive
Recently, a group of researchers analyzed 122 pregnant women and their neonates at the time of birth. All the women studied received 1 or both doses of a messenger RNA (mRNA)-based vaccine for COVID-19. Of the 122 women part of the study, 55 had received only the first dose of the vaccine while 67 women had received both doses of the mRNA vaccine by the time they gave birth; 85 women had received the Pfizer-BioNTech vaccine, and 37 women received the Moderna vaccine. The study is published on the preprint server, bioRxiv.
Approximately one-quarter of inter-birth intervals in low- and middle-income countries are less than 24 months in length, exposing infants to risks of prematurity, low birthweight, and death. Increased evidence of these health risks has emerged in the past few decades and, after a period of neglect, interest in postpartum family planning has followed, supported by organizations like WHO and USAID.
Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that the first patient was dosed in a Phase 1 pharmacokinetic clinical trial using Enhanze™ Technology (rHuPH20, recombinant human hyaluronidase) in a subcutaneous formulation of a Roche biologic.
Hotspur Technologies, announced today that Dr. Greg Sampognaro, Interventional Cardiologist at P & S Surgical Hospital in Monroe, Louisiana, successfully completed the first use of the GPSCath Balloon Dilatation Catheter in an intervention to treat a blocked peripheral artery.
PharmAthene, Inc. announced today that it has achieved significant progress in the development of its second generation anthrax vaccine, SparVax.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Rachel Lynn Siffring, DNP, FNP-BC 553 Clinton Ave, Albany, NY 12206-2738 Ph: (518) 689-0282 | Rachel Lynn Siffring, DNP, FNP-BC 553 Clinton Ave, Albany, NY 12206-2738 Ph: (518) 689-0282 |
News Archive
Recently, a group of researchers analyzed 122 pregnant women and their neonates at the time of birth. All the women studied received 1 or both doses of a messenger RNA (mRNA)-based vaccine for COVID-19. Of the 122 women part of the study, 55 had received only the first dose of the vaccine while 67 women had received both doses of the mRNA vaccine by the time they gave birth; 85 women had received the Pfizer-BioNTech vaccine, and 37 women received the Moderna vaccine. The study is published on the preprint server, bioRxiv.
Approximately one-quarter of inter-birth intervals in low- and middle-income countries are less than 24 months in length, exposing infants to risks of prematurity, low birthweight, and death. Increased evidence of these health risks has emerged in the past few decades and, after a period of neglect, interest in postpartum family planning has followed, supported by organizations like WHO and USAID.
Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that the first patient was dosed in a Phase 1 pharmacokinetic clinical trial using Enhanze™ Technology (rHuPH20, recombinant human hyaluronidase) in a subcutaneous formulation of a Roche biologic.
Hotspur Technologies, announced today that Dr. Greg Sampognaro, Interventional Cardiologist at P & S Surgical Hospital in Monroe, Louisiana, successfully completed the first use of the GPSCath Balloon Dilatation Catheter in an intervention to treat a blocked peripheral artery.
PharmAthene, Inc. announced today that it has achieved significant progress in the development of its second generation anthrax vaccine, SparVax.
› Verified 4 days ago
Dr. Terrence Flannery, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 500 Patroon Creek Blvd, Albany, NY 12206 Phone: 518-641-3217 Fax: 518-641-3209 | |
Pascuala C Reyes, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 113 Holland Ave, Albany, NY 12208 Phone: 518-626-5000 | |
Dr. Lorelei A Michels, D.O. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 638 Western Ave, Albany, NY 12203 Phone: 518-763-3312 Fax: 518-489-4040 | |
David A Robinson, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 315 S Manning Blvd, @ St. Peter's Hospital Er Dept., Albany, NY 12208 Phone: 518-525-1324 Fax: 518-383-4223 | |
Dr. Peter Alexander Vellis, D.O. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1400 Washington Ave, Albany, NY 12222 Phone: 518-442-5461 Fax: 518-442-5444 | |
Dr. Dan Richard Tobin, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 113 Holland Ave, Albany, NY 12208 Phone: 518-626-6125 | |
Jonathan Peter Teubl, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 315 S Manning Blvd, Albany, NY 12208 Phone: 518-525-1550 |